Bausch, formerly Valeant Pharmaceuticals, has paid down more than $24 billion of the $32 billion in leverage it owed five years ago from a debt-driven acquisition spree — which ended after a drug-pricing scandal.

January 4
2 Min Read
p19ipf54g419261tndmrl13hk1cff9.jpg
Load More